Adverse events during the titration phase of interferon-beta in remitting-relapsing multiple sclerosis are not predicted by body mass index nor by pharmacodynamic biomarkers
![Thumbnail](/xmlui/themes/Mirage2//images/thumbnails/thumn_cientif.png)
Identificadores![](/xmlui/themes/Mirage2//images/despl_identif.png)
Identificadores
Fecha de publicación
2013Título de revista
BMC Neurology
Tipo de contenido
Artigo
![](/xmlui/themes/Mirage2//images/final_lines.png)